Wire · regulatory
Drapeau's AI Deep Dive: The Price of Acceptance in Regulated AI
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
AI can rapidly generate candidates for pharmaceutical programs, but clear quality system evidence and human oversight remain essential to accept AI outputs in regulated manufacturing. The FDA enforces strict review requirements for AI-generated documents in GMP contexts, highlighting the substantial ongoing cost of human validation and regulatory acceptance.
This Wire brief sits within Fusion42's coverage of Pharma and Biotech.
◆ ◆ The Wire takeaway
You must build high-evidence review steps into your pharma AI workflows this week or risk barred use by regulators. The cost of human oversight dominates AI in regulated manufacturing but is unavoidable if you want market access.
◆ Coverage
1 source · 3 Nov 2026
◆ Related on Wire
◆ Topics